Adage Capital Partners
DYN icon

Adage Capital Partners’s Dyne Therapeutics DYN Stock Holding History

Adage Capital Partners’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.33M Sell
150,000
-850,000
-85% -$15.8M ﹤0.01% 839
2026
Q1 		$18.1M Sell
1,000,000
-4,172,000
-81% -$71.9M 0.03% 503
2025
Q4 		$101M Buy
5,172,000
+1,618,000
+46% +$30.6M 0.15% 127
2025
Q3 		$45M Buy
3,554,000
+363,000
+11% +$4.14M 0.07% 259
2025
Q2 		$30.4M Buy
+3,191,000
New +$35.1M 0.05% 348
2025
Q1 		– Sell
-1,950,000
Closed -$45.9M – 868
2024
Q4 		$45.9M Sell
1,950,000
-452,972
-19% -$13.4M 0.08% 233
2024
Q3 		$86.3M Sell
2,402,972
-925,028
-28% -$36.8M 0.15% 134
2024
Q2 		$117M Buy
3,328,000
+1,003,000
+43% +$29.1M 0.22% 84
2024
Q1 		$66M Buy
+2,325,000
New +$52.6M 0.12% 179
2023
Q3 		– Sell
-100,000
Closed -$1.13M – 888
2023
Q2 		$1.13M Sell
100,000
-500,000
-83% -$5.9M ﹤0.01% 765
2023
Q1 		$6.91M Buy
600,000
+200,000
+50% +$2.6M 0.02% 673
2022
Q4 		$4.64M Sell
400,000
-50,000
-11% -$579K 0.01% 757
2022
Q3 		$5.71M Sell
450,000
-120,000
-21% -$1.38M 0.01% 761
2022
Q2 		$3.92M Sell
570,000
-180,000
-24% -$1.24M 0.01% 828
2022
Q1 		$7.23M Buy
750,000
+650,000
+650% +$5.53M 0.01% 782
2021
Q4 		$1.19M Buy
100,000
+50,000
+100% +$703K ﹤0.01% 893
2021
Q3 		$812K Sell
50,000
-50,000
-50% -$886K ﹤0.01% 921
2021
Q2 		$2.1M Buy
+100,000
New +$1.88M ﹤0.01% 878

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Adage Capital Partners's DYN Position: Q2 2026 in Review

Adage Capital Partners reduced its Dyne Therapeutics (DYN) stake by 85% in Q2 2026, selling an estimated $15.8M and leaving 150,000 shares worth $3.33M. The position accounts for ﹤0.01% of the portfolio, ranked #839.

Adage Capital Partners first reported a position in DYN in Q2 2021 and has held it in 18 quarters since. The position peaked at $117M in Q2 2024. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Adage Capital Partners held 150,000 shares of Dyne Therapeutics worth $3.33M as of Q2 2026.
  • Adage Capital Partners sold 850,000 Dyne Therapeutics shares in Q2 2026, an estimated $15.8M.
  • Dyne Therapeutics made up ﹤0.01% of Adage Capital Partners's portfolio in Q2 2026, its #839 holding.
  • Adage Capital Partners first reported a position in Dyne Therapeutics in Q2 2021 and has held it in 18 quarters since.
  • Adage Capital Partners's Dyne Therapeutics position peaked at $117M in Q2 2024.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.